References (continued)

46. Jain RH, Schleicher SM, Atoria CL, Bach PB. Part B payment for drugs in Medicare: Phase 1 of CMS’ proposed pilot and its impact on oncology care: Memorial Sloan Kettering Cancer Center; 2016. Available from: http://drugpricinglab.org/wp-content/uploads/2016/04/Part-B-Payment-Phase-1-Report-042216.pdf. Accessed April 11, 2016.

47. Health Resources & Services Administration. 340B Drug Pricing Program. Washington, DC: US Department of Health & Human Services; 2017 [updated March 20, 2017]. Available from: https://www.hrsa.gov/opa/. Accessed April 6, 2017.

48. Pyenson BS, Fitch KV, Pelizzari PM. Cost drivers of cancer care: a retrospective analysis of Medicare and commercially insured population claim data, 2004–2014. New York, NY: Milliman; 2016. Available from: http://www.milliman.com/insight/2016/Cost-drivers-of-cancer-care-A-retrospective-analysis-of-Medicare-and-commercially-insured-population-claim-data-2004-2014/. Accessed April 6, 2017.

49. Dickson V. CMS finalizes site-neutral payment rule. New York, NY: Modern Healthcare; 2016 [updated November 1, 2106]. Available from: http://www.modernhealthcare.com/article/20161101/NEWS/ 161109982. Accessed April 6, 2017.

50. Avalere Health. Patient out-of-pocket costs for biosimilars in Medicare Part D. Washington, DC: Avalere Health; 2016. Available from: http://go.avalere.com/acton/attachment/12909/f-02c0/1/-/-/-/-/20160412_Patient%20OOP%20for%20Biosimilars%20in%20Part%20D.pdf. Accessed April 6, 2017.

51. Kelly C. Biosimilars pricing in Medicare Part D needs legislative fix, Avalere says. New York, NY: Pink Sheet Daily; 2016. Available from: https://pink.pharmamedtechbi.com/PS079306/Biosimilars-Pricing-In-Medicare-Part-D-Needs-Legislative-Fix-Avalere-Says. Accessed April 6, 2017.

52. Kopenski FR, Holcomb K. Understanding biosimilars and projecting the cost savings to employers: update. Seattle, WA: Milliman; 2015. Available from: http://www.milliman.com/insight/2015/Understanding-biosimilars-and-projecting-the-cost-savings-to-employers-Update/. Accessed April 6, 2017.

53. Banthia V. Biosimilar regulation: bringing the United States up to speed with other markets. Minn J Law Sci Technol. 2015;16(2):879–916.

54. Felix AE, Gupta A, Cohen JP, Riggs K. Barriers to market uptake of biosimilars in the US. GaBi J. 2016;3(3):108–115.

55. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;29(13):173.

56. Babar ZUD, Scahill S. Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature. Health Policy. 2014;117(3): 285–296.

57. IMS Institute for Healthcare Informatics. The role of generic medicines in sustaining healthcare systems: a European perspective. Parsippany, NJ: IMS Health; 2015. Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/IIHI_Generics_Healthcare_Brief.pdf. Accessed April 7, 2017.

58. Centers for Medicare & Medicaid Services. Oncology care model. Baltimore, MD: US Department of Health & Human Services; 2016 [updated January 6, 2017]. Available from: https://innovation.cms.gov/initiatives/oncology-care/. Accessed April 6, 2017.

59. Gold J. Accountable Care Organizations, explained. Menlo Park, CA: Kaiser Health News; 2015 [updated September 14, 2015]. Available from: http://khn.org/news/aco-accountable-care-organization-faq/. Accessed April 6, 2017.

60. Patel BN, Audet PR. A review of approaches for the management of specialty pharmaceuticals in the United States. Pharmacoeconomics. 2014;32(11):1105–1114.

Source: Cancer Management and Research.
Originally published June 1, 2017.